The final, formatted version of the article will be published soon.
MINI REVIEW article
Front. Biomater. Sci.
Sec. Delivery Systems and Controlled Release
Volume 4 - 2025 |
doi: 10.3389/fbiom.2025.1544465
This article is part of the Research Topic Innovative Immunotherapy Applications in Drug Delivery and Tissue Engineering View all articles
Advancing Immunotherapy with Emerging Adjuvant Agents: Mechanisms and Applications
Provisionally accepted- 1 University of Liverpool, Liverpool, United Kingdom
- 2 National Institute of Pharmaceutical Education and Research, Ahmedabad, Ahmedabad, Gujarat, India
- 3 Queen's University Belfast, Belfast, Northern Ireland, United Kingdom
Immunotherapy has emerged as a powerful approach in treating various diseases, yet its success often hinges on the efficacy of adjuvants, agents that boost immune responses to therapeutic targets. Traditional adjuvants have offered foundational support but may fall short in achieving the specificity and potency required for advanced therapies. This review highlights a new generation of adjuvants poised to address these limitations. We explore a range of innovative agents, including non-inflammatory nucleic acid adjuvants, bacterial derivatives, and synthetic molecules, which are redefining the role of adjuvants in immunotherapy. These emerging agents hold promise for enhancing immune responses while tailoring therapies to specific disease contexts, from cancer to infectious diseases. By examining the applications and potential of these adjuvants, this review aims to provide a comprehensive understanding of how they can advance immunotherapy to new levels of efficacy and precision.Through the development of these novel adjuvants, immunotherapy stands to achieve more targeted and sustained impacts, paving the way for improved outcomes in patient care.
Keywords: Immunotherapy, adjuvants, Vaccine, Cancer, infectious diseases
Received: 12 Dec 2024; Accepted: 22 Jan 2025.
Copyright: © 2025 Desai, Gotru, Salave and VORA. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
LALITKUMAR K VORA, Queen's University Belfast, Belfast, BT7 INN, Northern Ireland, United Kingdom
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.